Key result
Ticagrelor increases moderate-to-severe erectile dysfunction by ~104% vs clopidogrel at 6 months in men with STEMI.
Why the study?
AMI is strongly associated with erectile dysfunction, but the impact of P2Y 12 receptor inhibitor type and factors associated with moderate-to-severe ED remained to be evaluated.
Does ticagrelor compared to clopidogrel increase the risk of moderate-to-severe erectile dysfunction in male patients with STEMI following PCI?
RCT (n=59)
1:1
No
Does ticagrelor compared to clopidogrel increase the risk of moderate-to-severe erectile dysfunction in male patients with STEMI following PCI?
Answers are grounded in this paper and cite their sources.
Ticagrelor may worsen erectile function versus clopidogrel in male STEMI patients; challenges ticagrelor preference in DAPT and requires larger confirmation.
Background: Acute myocardial infarction (AMI) is strongly associated with erectile dysfunction (ED). This study evaluated the association between P2Y 12 receptor inhibitor type and ED, and factors associated with moderate-to-severe ED in high-risk patients with AMI. Methods The HEALING-AMI trial randomized patients with naïve ST-segment elevation myocardial infarction (STEMI) to dual antiplatelet therapy (DAPT) with either ticagrelor or clopidogrel. This substudy included 59 male patients who completed 6 months of DAPT (ticagrelor, n = 30; clopidogrel, n = 29). Erectile function [International Index of Erectile Function-5 (IIEF-5)], Bleeding Academic Research Consortium (BARC) bleeding, and dyspnoea were assessed using standardized questionnaires. Results At 6-month follow-up, moderate-to-severe ED (IIEF-5 ≤ 11) and bleeding episodes (predominantly BARC type 1) were observed in 47.5% and 54.2%, respectively. Compared with clopidogrel, ticagrelor was associated with a lower IIEF-5 score (9.7 ± 8.8 vs. 17.0 ± 7.8, p = 0.002) and lower platelet reactivity [32 ± 67 vs. 146 ± 55 P2Y12 reaction units (PRU) measured by VerifyNow, p < 0.001]. Moderate-to-severe ED was more common in patients treated with ticagrelor than in those treated with clopidogrel (63.3% vs. 31.0%). Bleeding episodes and platelet reactivity were also significantly associated with moderate-to-severe ED. In multivariable analysis, both P2Y 12 inhibitor type and bleeding episodes were independently associated with moderate-to-severe ED. After multivariable adjustment, ticagrelor-treated patients who experienced bleeding had an approximately 5.6-fold higher odds of moderate-to-severe ED than clopidogrel-treated patients without bleeding (95% CI 1.052–30.087, p = 0.044). Conclusions In male patients with STEMI, moderate-to-severe ED and bleeding episodes were common during DAPT. P2Y 12 inhibitor type (ticagrelor vs. clopidogrel) and bleeding episodes were associated with moderate-to-severe ED.
No takes yet. Share an insight, caveat, or question.
Choi et al. (2026) conducted an RCT in ST-segment elevation myocardial infarction (STEMI) (n=59). Ticagrelor vs. Clopidogrel (600 mg loading dose, then 75 mg once daily) was evaluated on Presence of moderate-to-severe erectile dysfunction (IIEF-5 ≤11) at 6-month follow-up (p=0.013). Ticagrelor was associated with a higher prevalence of moderate-to-severe erectile dysfunction compared to clopidogrel at 6 months in male patients with STEMI.
Synapse has enriched 10 related papers. Consider them for comparative context: